Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 443

1.

Public views regarding the responsibility of patients, clinicians, and institutions to participate in research in the United States.

Weinfurt KP, Lin L, Sugarman J.

Clin Trials. 2019 Jul 1:1740774519858917. doi: 10.1177/1740774519858917. [Epub ahead of print]

PMID:
31256635
2.

Ethical considerations for new HIV prevention trials.

Sugarman J, Celum CL, Donnell D, Mayer KH.

Lancet HIV. 2019 Jun 17. pii: S2352-3018(19)30184-5. doi: 10.1016/S2352-3018(19)30184-5. [Epub ahead of print] No abstract available.

PMID:
31221591
3.

Tibialis anterior muscle herniation in adolescents: A case series and review of the literature.

Clinite KL, Wyble A, Sugarman JL.

Pediatr Dermatol. 2019 Jun 18. doi: 10.1111/pde.13875. [Epub ahead of print]

PMID:
31215058
4.

Early experiences of independent advocates for potential HIV+ recipients of HIV+ donor organ transplants.

Bollinger JM, Eno A, Seaman S, Brown D, Van Pilsum Rasmussen SE, Tobian AAR, Segev DL, Durand CM, Sugarman J.

Clin Transplant. 2019 May 29:e13617. doi: 10.1111/ctr.13617. [Epub ahead of print]

PMID:
31140611
5.

In reply.

Dickert NW, Sugarman J.

Ann Emerg Med. 2019 Jun;73(6):692-693. doi: 10.1016/j.annemergmed.2019.01.011. No abstract available.

PMID:
31133186
6.

Addressing guideline and policy changes during pragmatic clinical trials.

Curtis LH, Dember LM, Vazquez MA, Murray D, DeBar L, Staman KL, Septimus E, Mor V, Volandes A, Wells BL, Huang SS, Green BB, Coronado G, Meyers CM, Tuzzio L, Hernandez AF, Sugarman J.

Clin Trials. 2019 May 14:1740774519845682. doi: 10.1177/1740774519845682. [Epub ahead of print]

PMID:
31084378
7.

Donald E. Polkinghorne (1936-2018).

Carter JW, Sugarman J, Wertz F.

Am Psychol. 2019 May-Jun;74(4):514. doi: 10.1037/amp0000380.

PMID:
31070413
8.

Preventive Misconception and Risk Behaviors in a Multinational HIV Prevention Trial.

Sugarman J, Lin L, Baeten JM, Palanee-Phillips T, Brown ER, Matovu Kiweewa F, Mgodi NM, Nair G, Siva S, Seils DM, Weinfurt KP; MTN-020/ASPIRE Study Team.

AJOB Empir Bioeth. 2019 Apr-Jun;10(2):79-87. doi: 10.1080/23294515.2019.1593257. Epub 2019 Apr 19.

9.

Safety and efficacy of halobetasol propionate lotion 0.01% in the treatment of moderate to severe plaque psoriasis: a pooled analysis of 2 phase 3 studies.

Sugarman JL, Weiss JS, Tanghetti EA, Soung J, Yamauchi PS, Lin T, Harris S, Martin G, Pillai R.

Cutis. 2018 Feb;102(2):111-116.

PMID:
30893392
10.

Recommendations for analytical antiretroviral treatment interruptions in HIV research trials-report of a consensus meeting.

Julg B, Dee L, Ananworanich J, Barouch DH, Bar K, Caskey M, Colby DJ, Dawson L, Dong KL, Dubé K, Eron J, Frater J, Gandhi RT, Geleziunas R, Goulder P, Hanna GJ, Jefferys R, Johnston R, Kuritzkes D, Li JZ, Likhitwonnawut U, van Lunzen J, Martinez-Picado J, Miller V, Montaner LJ, Nixon DF, Palm D, Pantaleo G, Peay H, Persaud D, Salzwedel J, Salzwedel K, Schacker T, Sheikh V, Søgaard OS, Spudich S, Stephenson K, Sugarman J, Taylor J, Tebas P, Tiemessen CT, Tressler R, Weiss CD, Zheng L, Robb ML, Michael NL, Mellors JW, Deeks SG, Walker BD.

Lancet HIV. 2019 Apr;6(4):e259-e268. doi: 10.1016/S2352-3018(19)30052-9. Epub 2019 Mar 15. Review.

PMID:
30885693
11.

Ethical Issues Involved in Grateful Patient Fundraising-Reply.

Collins ME, Rum SA, Sugarman J.

JAMA. 2019 Jan 29;321(4):408. doi: 10.1001/jama.2018.18672. No abstract available.

PMID:
30694313
12.

Novel tretinoin 0.05% lotion for the once-daily treatment of moderate-to-severe acne vulgaris in a preadolescent population.

Eichenfield LF, Sugarman JL, Guenin E, Harris S, Bhatt V.

Pediatr Dermatol. 2019 Mar;36(2):193-199. doi: 10.1111/pde.13744. Epub 2019 Jan 18.

13.

Tackling Ethical Challenges of Premature Delivery of Stem Cell-Based Therapies: ISSCR 2018 Annual Meeting Focus Session Report.

Sugarman J, Barker RA, Kerridge I, Lysaght T, Pellegrini G, Sipp D, Tanner C.

Stem Cell Reports. 2018 Nov 13;11(5):1021-1025. doi: 10.1016/j.stemcr.2018.10.020.

14.

Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial.

Landovitz RJ, Li S, Grinsztejn B, Dawood H, Liu AY, Magnus M, Hosseinipour MC, Panchia R, Cottle L, Chau G, Richardson P, Marzinke MA, Hendrix CW, Eshleman SH, Zhang Y, Tolley E, Sugarman J, Kofron R, Adeyeye A, Burns D, Rinehart AR, Margolis D, Spreen WR, Cohen MS, McCauley M, Eron JJ.

PLoS Med. 2018 Nov 8;15(11):e1002690. doi: 10.1371/journal.pmed.1002690. eCollection 2018 Nov.

15.

Regional differences between people who inject drugs in an HIV prevention trial integrating treatment and prevention (HPTN 074): a baseline analysis.

Lancaster KE, Hoffman IF, Hanscom B, Ha TV, Dumchev K, Susami H, Rose S, Go VF, Reifeis SA, Mollan KR, Hudgens MG, Piwowar-Manning EM, Richardson P, Dvoriak S, Djoerban Z, Kiriazova T, Zeziulin O, Djauzi S, Ahn CV, Latkin C, Metzger D, Burns DN, Sugarman J, Strathdee SA, Eshleman SH, Clarke W, Donnell D, Emel L, Sunner LE, McKinstry L, Sista N, Hamilton EL, Lucas JP, Duong BD, Van Vuong N, Sarasvita R, Miller WC; HPTN 074 Study Team.

J Int AIDS Soc. 2018 Oct;21(10):e25195. doi: 10.1002/jia2.25195.

16.

Biometrics and public health surveillance in criminalised and key populations: policy, ethics, and human rights considerations.

Kavanagh MM, Baral SD, Milanga M, Sugarman J.

Lancet HIV. 2018 Oct 5. pii: S2352-3018(18)30243-1. doi: 10.1016/S2352-3018(18)30243-1. [Epub ahead of print] Review.

PMID:
30305236
17.

Long-term safety results from a phase 3 open-label study of a fixed combination halobetasol propionate 0.01% and tazarotene 0.045% lotion in moderate-to-severe plaque psoriasis.

Lebwohl MG, Sugarman JL, Gold LS, Pariser DM, Lin T, Pillai R, Martin G, Harris S, Israel R.

J Am Acad Dermatol. 2019 Jan;80(1):282-285. doi: 10.1016/j.jaad.2018.09.002. Epub 2018 Sep 15. No abstract available.

18.

A scalable, integrated intervention to engage people who inject drugs in HIV care and medication-assisted treatment (HPTN 074): a randomised, controlled phase 3 feasibility and efficacy study.

Miller WC, Hoffman IF, Hanscom BS, Ha TV, Dumchev K, Djoerban Z, Rose SM, Latkin CA, Metzger DS, Lancaster KE, Go VF, Dvoriak S, Mollan KR, Reifeis SA, Piwowar-Manning EM, Richardson P, Hudgens MG, Hamilton EL, Sugarman J, Eshleman SH, Susami H, Chu VA, Djauzi S, Kiriazova T, Bui DD, Strathdee SA, Burns DN.

Lancet. 2018 Sep 1;392(10149):747-759. doi: 10.1016/S0140-6736(18)31487-9.

PMID:
30191830
19.

Navigating the Ethical Boundaries of Grateful Patient Fundraising.

Collins ME, Rum SA, Sugarman J.

JAMA. 2018 Sep 11;320(10):975-976. doi: 10.1001/jama.2018.11655. No abstract available.

PMID:
30178043
20.

Perceptions of HIV cure research among people living with HIV in Australia.

Power J, Westle A, Dowsett GW, Lucke J, Tucker JD, Sugarman J, Lewin SR, Hill S, Brown G, Wallace J, Richmond J.

PLoS One. 2018 Aug 24;13(8):e0202647. doi: 10.1371/journal.pone.0202647. eCollection 2018.

21.

Ethical Considerations in the Manufacture, Sale, and Distribution of Genome Editing Technologies.

Sugarman J, Shivakumar S, Rook M, Loring JF, Rehmann-Sutter C, Taupitz J, Reinhard-Rupp J, Hildemann S.

Am J Bioeth. 2018 Aug;18(8):3-6. doi: 10.1080/15265161.2018.1489653. No abstract available.

PMID:
30133390
22.

Rapid Onset of Action in Patients With Moderate-to-Severe Plaque Psoriasis With Halobetasol 0.01%/Tazarotene 0.045% Fixed Combination.

Stein Gold L, Kircik LH, Pariser D, Sugarman JL, Lin T, Kang R, Pillai R.

J Drugs Dermatol. 2018 Aug 1;17(8):863-868.

PMID:
30124725
23.

Safety and Efficacy of a Fixed Combination Halobetasol and Tazarotene Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: A Pooled Analysis of Two Phase 3 Studies.

Sugarman JL, Weiss J, Tanghetti EA, Bagel J, Yamauchi PS, Stein Gold L, Lin T, Martin G, Pillai R, Israel R.

J Drugs Dermatol. 2018 Aug 1;17(8):855-861.

PMID:
30124724
24.

Ethics and Regulatory Barriers to Research in Emergency Settings.

Dickert NW, Sugarman J.

Ann Emerg Med. 2018 Oct;72(4):386-388. doi: 10.1016/j.annemergmed.2018.05.025. Epub 2018 Jul 19. No abstract available.

PMID:
30031559
25.

Ethical Issues and Recommendations in Grateful Patient Fundraising and Philanthropy.

Collins ME, Rum S, Wheeler J, Antman K, Brem H, Carrese J, Glennon M, Kahn J, Ohman EM, Jagsi R, Konrath S, Tovino S, Wright S, Sugarman J; Participants in the Summit on the Ethics of Grateful Patient Fundraising.

Acad Med. 2018 Nov;93(11):1631-1637. doi: 10.1097/ACM.0000000000002365.

26.

Does moisturizing the skin equate with barrier repair therapy?

Elias PM, Sugarman J.

Ann Allergy Asthma Immunol. 2018 Dec;121(6):653-656.e2. doi: 10.1016/j.anai.2018.07.008. Epub 2018 Aug 10. No abstract available.

PMID:
30009880
27.

Halobetasol 0.01%/Tazarotene 0.045% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Maintenance of Therapeutic Effect After Cessation of Therapy.

Pariser DM, Green LJ, Stein Gold L, Sugarman JL, Lin T, Pillai R.

J Drugs Dermatol. 2018 Jul 1;17(7):723-726.

PMID:
30005093
28.

Development and implementation of participant safety plans for international research with stigmatised populations.

Sugarman J, Barnes M, Rose S, Dumchev K, Sarasvita R, Viet HT, Zeziulin O, Susami H, Go V, Hoffman I, Miller WC.

Lancet HIV. 2018 Aug;5(8):e468-e472. doi: 10.1016/S2352-3018(18)30073-0. Epub 2018 Jun 24.

PMID:
29950284
29.

Emerging stem cell ethics.

Sipp D, Munsie M, Sugarman J.

Science. 2018 Jun 22;360(6395):1275. doi: 10.1126/science.aau4720. No abstract available.

PMID:
29930112
30.

Editors' Introduction to the Special Section on Ethics, Policy, and Autologous Cellular Therapies.

Lysaght T, Sugarman J.

Perspect Biol Med. 2018;61(1):1-6. doi: 10.1353/pbm.2018.0023. No abstract available.

PMID:
29805144
31.

Investigator Disclosure and Advanced Cancer Patient Understanding of Informed Consent and Prognosis in Phase I Clinical Trials.

Hlubocky FJ, Kass NE, Roter D, Larson S, Wroblewski KE, Sugarman J, Daugherty CK.

J Oncol Pract. 2018 Jun;14(6):e357-e367. doi: 10.1200/JOP.18.00028. Epub 2018 May 22.

32.

Stabilized single-injection inactivated polio vaccine elicits a strong neutralizing immune response.

Tzeng SY, McHugh KJ, Behrens AM, Rose S, Sugarman JL, Ferber S, Langer R, Jaklenec A.

Proc Natl Acad Sci U S A. 2018 Jun 5;115(23):E5269-E5278. doi: 10.1073/pnas.1720970115. Epub 2018 May 21.

33.

Willingness to Donate Organs Among People Living With HIV.

Nguyen AQ, Anjum SK, Halpern SE, Kumar K, Van Pilsum Rasmussen SE, Doby B, Shaffer AA, Massie AB, Tobian AAR, Segev DL, Sugarman J, Durand CM.

J Acquir Immune Defic Syndr. 2018 Sep 1;79(1):e30-e36. doi: 10.1097/QAI.0000000000001760.

PMID:
29781880
34.

Revisiting Blood Safety Practices Given Emerging Data about Zika Virus.

Bloch EM, Ness PM, Tobian AAR, Sugarman J.

N Engl J Med. 2018 May 10;378(19):1837-1841. doi: 10.1056/NEJMsb1704752. No abstract available.

35.

Evaporative Cooling Hydrogel Packaging for Storing Biologics Outside of the Cold Chain.

Ferber S, Behrens AM, McHugh KJ, Rosenberg EM, Linehan AR, Sugarman JL, Jayawardena HSN, Langer R, Jaklenec A.

Adv Healthc Mater. 2018 Jul;7(14):e1800220. doi: 10.1002/adhm.201800220. Epub 2018 May 7.

PMID:
29732715
36.

Perceptions, motivations, and concerns about living organ donation among people living with HIV.

Van Pilsum Rasmussen SE, Henderson ML, Bollinger J, Seaman S, Brown D, Durand CM, Segev DL, Sugarman J.

AIDS Care. 2018 Dec;30(12):1595-1599. doi: 10.1080/09540121.2018.1469724. Epub 2018 May 3.

PMID:
29724118
37.

Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: Results of 2 phase 3 randomized controlled trials.

Gold LS, Lebwohl MG, Sugarman JL, Pariser DM, Lin T, Martin G, Pillai R, Israel R, Ramakrishna T.

J Am Acad Dermatol. 2018 Aug;79(2):287-293. doi: 10.1016/j.jaad.2018.03.040. Epub 2018 Apr 1.

38.

Developing drugs for treatment of atopic dermatitis in children (≥3 months to <18 years of age): Draft guidance for industry.

Siegfried EC, Jaworski JC, Eichenfield LF, Paller A, Hebert AA, Simpson EL, Altman E, Arena C, Blauvelt A, Block J, Boguniewicz M, Chen S, Cordoro K, Hanna D, Horii K, Hultsch T, Lee J, Leung DY, Lio P, Milner J, Omachi T, Schneider C, Schneider L, Sidbury R, Smith T, Sugarman J, Taha S, Tofte S, Tollefson M, Tom WL, West DP, Whitney L, Zane L.

Pediatr Dermatol. 2018 May;35(3):303-322. doi: 10.1111/pde.13452. Epub 2018 Mar 30.

PMID:
29600515
39.

Direct-Acting Antiviral Prophylaxis in Kidney Transplantation From Hepatitis C Virus-Infected Donors to Noninfected Recipients: An Open-Label Nonrandomized Trial.

Durand CM, Bowring MG, Brown DM, Chattergoon MA, Massaccesi G, Bair N, Wesson R, Reyad A, Naqvi FF, Ostrander D, Sugarman J, Segev DL, Sulkowski M, Desai NM.

Ann Intern Med. 2018 Apr 17;168(8):533-540. doi: 10.7326/M17-2871. Epub 2018 Mar 6.

40.

Implementing post-trial access plans for HIV prevention research.

Paul A, Merritt MW, Sugarman J.

J Med Ethics. 2018 May;44(5):354-358. doi: 10.1136/medethics-2017-104637. Epub 2018 Feb 27.

PMID:
29487116
41.

Climate of Respect Evaluation in ICUs: Development of an Instrument (ICU-CORE).

Beach MC, Topazian R, Chan KS, Sugarman J, Geller G.

Crit Care Med. 2018 Jun;46(6):e502-e507. doi: 10.1097/CCM.0000000000003069.

42.

Quantitative self-assembly prediction yields targeted nanomedicines.

Shamay Y, Shah J, Işık M, Mizrachi A, Leibold J, Tschaharganeh DF, Roxbury D, Budhathoki-Uprety J, Nawaly K, Sugarman JL, Baut E, Neiman MR, Dacek M, Ganesh KS, Johnson DC, Sridharan R, Chu KL, Rajasekhar VK, Lowe SW, Chodera JD, Heller DA.

Nat Mater. 2018 Apr;17(4):361-368. doi: 10.1038/s41563-017-0007-z. Epub 2018 Feb 5.

43.

Pediatric psoriasis: Evolving perspectives.

Eichenfield LF, Paller AS, Tom WL, Sugarman J, Hebert AA, Friedlander SF, Siegfried E, Silverberg N, Cordoro KM.

Pediatr Dermatol. 2018 Mar;35(2):170-181. doi: 10.1111/pde.13382. Epub 2018 Jan 4. Review.

PMID:
29314219
44.

Ethical Considerations Concerning Amnioinfusions for Treating Fetal Bilateral Renal Agenesis.

Sugarman J, Anderson J, Baschat AA, Herrera Beutler J, Bienstock JL, Bunchman TE, Desai NM, Gates E, Goldberg A, Grimm PC, Henry LM, Jelin EB, Johnson E, Hertenstein CB, Mastroianni AC, Mercurio MR, Neu A, Nogee LM, Polzin WJ, Ralston SJ, Ramus RM, Singleton MK, Somers MJG, Wang KC, Boss R.

Obstet Gynecol. 2018 Jan;131(1):130-134. doi: 10.1097/AOG.0000000000002416. Review.

PMID:
29215523
45.

HIV viral load monitoring among key populations in low- and middle-income countries: challenges and opportunities.

Schwartz SR, Kavanagh MM, Sugarman J, Solomon SS, Njindam IM, Rebe K, Quinn TC, Toure-Kane C, Beyrer C, Baral S.

J Int AIDS Soc. 2017 Nov;20 Suppl 7. doi: 10.1002/jia2.25003.

46.

Bringing science and advocacy together to address health needs of people who inject drugs.

Dawson L, Strathdee SA, London AJ, Lancaster KE, Klitzman R, Hoffman I, Rose S, Sugarman J.

J Med Ethics. 2018 Mar;44(3):165-166. doi: 10.1136/medethics-2017-104591. Epub 2017 Oct 27. No abstract available.

PMID:
29079557
47.

HIV cure research: print and online media reporting in Australia.

Power J, Fileborn B, Dowsett GW, Lucke J, Brown G, Ellard J, Lewin SR, Tucker JD, Slavin S, Sugarman J, Hill S.

J Virus Erad. 2017 Oct 1;3(4):229-235.

48.

Epidermal nevus syndromes: New insights into whorls and swirls.

Asch S, Sugarman JL.

Pediatr Dermatol. 2018 Jan;35(1):21-29. doi: 10.1111/pde.13273. Epub 2017 Oct 16. Review.

PMID:
29044700
49.

Fifty-two words for snow: dermatologists naming epidermal naevi.

Asch S, Sugarman JL.

Br J Dermatol. 2018 Jan;178(1):296. doi: 10.1111/bjd.16012. Epub 2017 Nov 28. No abstract available.

PMID:
28960256
50.

Pragmatic clinical trials embedded in healthcare systems: generalizable lessons from the NIH Collaboratory.

Weinfurt KP, Hernandez AF, Coronado GD, DeBar LL, Dember LM, Green BB, Heagerty PJ, Huang SS, James KT, Jarvik JG, Larson EB, Mor V, Platt R, Rosenthal GE, Septimus EJ, Simon GE, Staman KL, Sugarman J, Vazquez M, Zatzick D, Curtis LH.

BMC Med Res Methodol. 2017 Sep 18;17(1):144. doi: 10.1186/s12874-017-0420-7.

Supplemental Content

Loading ...
Support Center